HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics for patients with certain cancers. The Company focuses on the development of therapies for skin, lung and prostate cancers in the United States market. The Company's is engaged to develop and to commercialize SUBA-Itraconazole Capsules for the treatment of human cancer via oral administration. The Company's SUBA technology (which stands for super bioavailability) is designed to improve the bioavailability of orally administered drugs that are soluble.